Table 3.

Approved indications^a for the main botulinum neurotoxin products available in the US and EU^b

Indicationa	OnabotulinumtoxinA	AbobotulinumtoxinA	IncobotulinumtoxinA
Therapeutic
Strabismus	US	–	–
Blepharopsasm	US, EU	EU	US, EU
Hemifacial spasm	EU	EU	–
Cervical dystonia	US, EU	US, EU	US, EU
Primary axillary hyperhidrosis	US, EU	–	–
Focal upper-limb spasticity	US, EU	EU	EU
Juvenile cerebral palsy (dynamic equinus foot deformity)	EU	EU	–
Chronic migraine	US, EU	–	–
Neurogenic detrusor overactivity	US, EU	–	–
Overactive bladder	US, EU	–	–
Aesthetic
Glabellar lines	US, EU	US, EU	US, EU
Crow’s feet lines	US, EUc

Notes:

^aPrecise indication wording and associated limitations vary from country to country. Consult local labeling for details;

^bmajority of EU5 countries (France, Germany, Italy, Spain, United Kingdom);

^cEU mutual recognition procedure completed October 18, 2013.

Abbreviation: EU, European Union.